Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Katrin H. Preller,Joachim Scholpp,Andreas Wunder,Holger Rosenbrock
DOI: https://doi.org/10.1016/j.biopsych.2024.01.009
IF: 12.81
2024-01-26
Biological Psychiatry
Abstract:Schizophrenia is a chronic mental illness affecting up to 1% of the population. While therapies for positive symptoms are available and efficacious, cognitive and negative symptoms remain an unmet need after decades of research. New developments in the field of neuroimaging are accelerating our knowledge gain regarding the underlying pathophysiology of symptoms in schizophrenia and psychosis spectrum disorders, inspiring new targets for drug development. However, no validated and qualified biomarkers are currently available to support the development of new therapeutics. This review paper summarizes the current use of neuroimaging technology in clinical drug development for psychotic disorders. Exemplified by drug development programs targeting NMDA receptor hypofunction, we show that neuroimaging results play a critical role in target discovery and establishing target engagement and dose selection. Furthermore, pharmacological neuroimaging may provide response biomarkers that allow for early decision making in proof-of-concept studies leveraging pharmacological challenge models in healthy volunteers. That said, response and predictive biomarkers in patient populations – while starting to be evaluated – continue to play a limited role. Novel approaches to neuroimaging data acquisition and analysis may aid the establishment of biomarkers that are predictive at the individual level in the future. Yet, various gaps in knowledge need to be addressed and biomarkers need to be validated to establish them as "fit-for-purpose" in drug development.
neurosciences,psychiatry
What problem does this paper attempt to address?